1-5 of 5
accessory bone
Close
Sort by
Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth H. Shain, MD, Jacob Laubach, MD, Patrick Henrick, James Vredenburg, MD, Pamela Crilley, MD, Michael Constantine, MD, Caroline Block, MD, Frank G. Basile, MD, Joseph Cappuccio, Abdel Kareem Azab, BPharm, PhD, Emily Lai, Aaron Caola, Ranjit Banwait, Alexandra Savell, Nikhil C. Munshi, MD, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Kimberly Noonan, NP, Kenneth C. Anderson, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 4256.
https://doi.org/10.1182/blood.V126.23.4256.4256
Published: 2015
Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson
Journal: Blood
Blood (2014) 124 (21): 5777.
https://doi.org/10.1182/blood.V124.21.5777.5777
Published: 2014
Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth Shain, MD, PhD, Courtney Hanlon, Ranjit Banwait, Abdel Kareem Azab, Bpharm, PhD, Jacob P. Laubach, MD, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Stacey Chuma, BSN, Erica N Boswell, BS, Patrick Mostyn, Leblebjian Houry, PharmD, Kenneth C. Anderson, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2013) 122 (21): 1947.
https://doi.org/10.1182/blood.V122.21.1947.1947
Published: 2013
Journal Articles

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Abdel Kareem Azab, Bpharm, PhD, Phong Quang, BS, Jacob P. Laubach, MD, Amanda Donovan, BS, Meghan Bagshaw, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 1874.
https://doi.org/10.1182/blood.V118.21.1874.1874
Published: 2011
Journal Articles

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Irene Ghobrial, MD, Abdel Kareem A. Azab, PhD, BSPharm, Jacob P. Laubach, MD, MPP, Ranjit Banwait, Meghan Rourke, Phong Quang, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Amy Sam, Eric Still, Brittany Morgan, Kenneth C. Anderson, Paul G Richardson
Journal: Blood
Blood (2010) 116 (21): 1943.
https://doi.org/10.1182/blood.V116.21.1943.1943
Published: 2010